Please login to the form below

Not currently logged in
Email:
Password:

TiGenix appoints Dr Marie Paule Richard

She takes on role as chief medical officer and brings experience from Aicuris and Crucell

Dr Marie Paule Richard appointed at TiGenixBelgium-based cell therapy company TiGenix has appointed Dr Marie Paule Richard as its new chief medical officer.

An immunologist with over 25 years of experience in the global biopharmaceutical industry, Richard has previously served as chief medical officer at Aicuris in Germany and vice president of clinical development, pharmacovigilance and medical affairs at Crucell in Switzerland.

She joins TiGenix from PharmaBioDev, the consultancy she led, and also brings experience to the role from GlaxoSmithKline and Sanofi.

In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is in phase III trials for complex perianal fistulas in Crohn's disease.

Eduardo Brave, chief executive officer at TiGenix, said: “The whole focus of TiGenix is the successful clinical development, regulatory approval and future commercialisation of the new products in its development pipeline.

“We are very fortunate to have biopharma development, regulatory and commercialisation heavyweight Marie Paule joining the TiGenix management team. She brings a wealth of experience and ability in areas which will be key for the success of the company in the near future.”

2nd September 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics